Bluefin Achieves Girocard Certification for the Newland Payment Technology N950 AIO smartPOS
18.2.2025 15:00:00 CET | Business Wire | Press release
Bluefin has achieved the German Banking Industry Committee’s (GBIC German: Deutsche Kreditwirtschaft) Girocard certification on the Newland NPT N950 AIO smartPOS terminal. This certification enables German merchants to adopt next-generation SmartPOS devices while simplifying Girocard payment acceptance through Bluefin’s TECS Engine, a global payments platform.
Bluefin’s TECS Engine provides omnichannel payment solutions to Acquirers, Payment Service Providers, POS system providers, Independent Software Vendors (ISVs) and other merchant aggregators around the globe offering a cloud-based Payments Platform-as-a-Service, including Bluefin’s payment and data security solutions, P2PE and universal tokenization.
As the leading debit card in Germany, Girocard conducted 7.5 billion transactions in 2023. With Girocard certification on the Newland N950 AIO smartPOS terminal, the German market will benefit from an open platform with access to new generations of SmartPOS devices and streamlined Girocard payment acceptance while benefitting from lower merchant service fees.
“Achieving Girocard certification for the Newland N950 AIO smartPOS is a key milestone for TECS and Bluefin, reinforcing our commitment to delivering secure, innovative, and globally adaptable payment solutions,” said Anton Scheiber, International Sales & Business Development Director, Bluefin. “This certification provides new opportunities for merchants in Germany, giving them access to innovative SmartPOS technology while ensuring seamless Girocard payment acceptance.”
The Newland N950 is an Android SmartPOS terminal designed for seamless and secure payments across industries like retail, hospitality, and dining. Featuring a sleek touchscreen display and support for multiple payment methods – including chip and PIN, contactless, NFC, and QR-code payments – the N950 enhances customer engagement while streamlining transactions.
“We are excited to partner with Bluefin to bring the Newland N950 to the German market with Girocard certification,” said Kazem Aminaee, International President at Newland Payment Technology. “As a next-generation SmartPOS solution, the N950 combines advanced payment technology with a flexible platform, empowering businesses to enhance their payment experience while supporting Germany’s leading domestic debit card.”
About Bluefin
Bluefin is the recognized integrated payments leader in encryption and tokenization technologies that protect payments and sensitive data. Our product suite includes solutions for contactless, face-to-face, call center, mobile, E-commerce and unattended payments and data in the healthcare, higher education, government and nonprofit industries. The company’s 300 global partners serve 35,000 connected enterprise and software clients operating in 60 countries. Bluefin is a Participating Organization (PO) of the PCI Security Standards Council (SSC) and is headquartered in Atlanta, with offices in Waterford, Ireland and Vienna, Austria. For more information, visit https://www.bluefin.com/.
About Newland NPT
Newland NPT (Newland Payment Technology) is a leading global provider of payment acceptance technology. With over 30 years’ experience supplying best-in-class solutions, and working with partners in over 120 countries, Newland has successfully deployed over 100 million payment devices worldwide. For more information, visit https://www.newlandnpt.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218500456/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom